Universal Ibogaine Inc. (IBOGF)
USD 0.02
(0.0%)
USD 0.02
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 2.37 Million CAD | 126.62% |
| 2021 | 1.04 Million CAD | 4723.55% |
| 2020 | 21.72 Thousand CAD | 8.12% |
| 2019 | 20.09 Thousand CAD | -21.01% |
| 2018 | 25.43 Thousand CAD | 354.23% |
| 2017 | 5600.00 CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 3.36 Million CAD | 11.07% |
| 2023 Q1 | 3.02 Million CAD | 27.55% |
| 2023 Q3 | 3.67 Million CAD | 9.24% |
| 2022 FY | 2.37 Million CAD | 126.62% |
| 2022 Q1 | 3.1 Million CAD | -39.5% |
| 2022 Q4 | 2.37 Million CAD | -9.65% |
| 2022 Q3 | 2.62 Million CAD | 0.0% |
| 2021 Q1 | 71.18 Thousand CAD | 72.61% |
| 2021 FY | 1.04 Million CAD | 4723.55% |
| 2021 Q4 | 5.13 Million CAD | 133.15% |
| 2021 Q3 | 2.2 Million CAD | 2723.78% |
| 2021 Q2 | 78.02 Thousand CAD | 9.61% |
| 2020 Q2 | 6837.00 CAD | -74.61% |
| 2020 Q1 | 26.93 Thousand CAD | 13.07% |
| 2020 FY | 21.72 Thousand CAD | 8.12% |
| 2020 Q4 | 41.24 Thousand CAD | 89.85% |
| 2020 Q3 | 21.72 Thousand CAD | 217.74% |
| 2019 Q3 | 20.09 Thousand CAD | -21.34% |
| 2019 FY | 20.09 Thousand CAD | -21.01% |
| 2019 Q1 | 15.07 Thousand CAD | -49.41% |
| 2019 Q2 | 25.54 Thousand CAD | 69.48% |
| 2019 Q4 | 23.81 Thousand CAD | 18.54% |
| 2018 Q4 | 29.78 Thousand CAD | 17.11% |
| 2018 Q1 | 63.63 Thousand CAD | 178.49% |
| 2018 FY | 25.43 Thousand CAD | 354.23% |
| 2018 Q3 | 25.43 Thousand CAD | 0.0% |
| 2017 FY | 5600.00 CAD | 0.0% |
| 2017 Q4 | 22.84 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioxytran, Inc. | 3.24 Million USD | 26.922% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 95.545% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -463.294% |
| SQZ Biotechnologies Company | 50.03 Million USD | 95.254% |
| Intellipharmaceutics International Inc. | 12 Million USD | 80.226% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 96.723% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 95.976% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 38.343% |
| Marizyme, Inc. | 26.67 Million USD | 91.098% |
| Genus plc | 485 Million USD | 99.51% |
| Pharming Group N.V. | 244.07 Million USD | 99.027% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -18.135% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 5.63% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 37.509% |
| ContraFect Corporation | 32.53 Million USD | 92.7% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 37.96% |
| IMV Inc. | 37.93 Million USD | 93.74% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 79.838% |
| ONE Bio Corp. | 27.49 Million USD | 91.364% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 96.933% |
| Mesoblast Limited | 188.44 Million USD | 98.74% |
| MultiCell Technologies, Inc. | 1617.67 USD | -146695.453% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 97.137% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.821% |
| Neon Bloom, Inc. | 1.22 Million USD | -93.659% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 53.854% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 75.217% |
| Biomind Labs Inc. | 1.49 Million USD | -58.458% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 73.738% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 87.097% |
| Skye Bioscience, Inc. | 14.07 Million USD | 83.125% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -65.613% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 59.356% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1571.182% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -19.853% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 74.914% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1080.744% |
| Accustem Sciences Inc. | 1.07 Million USD | -120.032% |
| EV Biologics, Inc. | 2.11 Million USD | -12.274% |
| Q BioMed Inc. | 8.13 Million USD | 70.802% |
| GB Sciences, Inc. | 5.41 Million USD | 56.167% |
| Alpha Cognition Inc. | 7.16 Million USD | 66.856% |
| CSL Limited | 18.62 Billion USD | 99.987% |
| Agentix Corp. | 2.51 Million USD | 5.413% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.0% |
| Enzolytics Inc. | 365.26 Million USD | 99.35% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 67.39 Million USD | 96.477% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -183.126% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 58.671% |
| argenx SE | 444.95 Million USD | 99.466% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 96.83% |
| HST Global, Inc. | 593.59 Thousand USD | -300.05% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -38.545% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -88.586% |
| Halberd Corporation | 728.71 Thousand USD | -225.869% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 90.404% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 35.21% |
| Zenith Capital Corp. | 27.56 Thousand USD | -8513.537% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 80.05% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 36.409% |
| AVAX Technologies, Inc. | 3.99 Million USD | 40.54% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -248.788% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 12.427% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -895.025% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | 69.791% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -3448.037% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 95.276% |
| Kadimastem Ltd | 3.5 Million USD | 32.247% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | 85.069% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -411.012% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -8556.239% |
| LadRx Corporation | 2.2 Million USD | -7.913% |
| Cell Source, Inc. | 15.8 Million USD | 84.977% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -5212.927% |
| Regen BioPharma, Inc. | 5.45 Million USD | 56.489% |
| Regen BioPharma, Inc. | 5.45 Million USD | 56.489% |
| Affymax, Inc. | 8.87 Million USD | 73.231% |
| Mobile Lads Corp. | 1.31 Million USD | -80.79% |
| Itoco Inc. | 1.65 Million USD | -43.645% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -15.749% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 60.743% |
| International Stem Cell Corporation | 5.27 Million USD | 55.0% |
| CytoDyn Inc. | 127.89 Million USD | 98.143% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -5581.155% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -51.602% |
| Qrons Inc. | 1.48 Million USD | -59.511% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 78.501% |
| SYBLEU INC | 681.41 Thousand USD | -248.491% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -193.606% |
| Rebus Holdings, Inc. | 5.24 Million USD | 54.699% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 61.083% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -279.455% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 48.568% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 94.208% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 89.335% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -17.245% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 56.651% |
| Neutra Corp. | 973.52 Thousand USD | -143.923% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 91.816% |
| PureTech Health plc | 125.58 Million USD | 98.109% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 36.796% |
| IXICO plc | 1.9 Million USD | -24.963% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 88.433% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 97.702% |
| CSL Limited | 18.62 Billion USD | 99.987% |
| Cellectis S.A. | 249.36 Million USD | 99.048% |